Chemomab Therapeutics Ltd. (2QV0.F)
- Previous Close
1.0600 - Open
1.1100 - Bid 1.0800 x --
- Ask 1.2100 x --
- Day's Range
1.0900 - 1.1100 - 52 Week Range
0.5700 - 2.3200 - Volume
16,836 - Avg. Volume
303 - Market Cap (intraday)
21.477M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6900 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
www.chemomab.comRecent News: 2QV0.F
View MorePerformance Overview: 2QV0.F
Trailing total returns as of 4/27/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2QV0.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2QV0.F
View MoreValuation Measures
Market Cap
21.81M
Enterprise Value
9.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.10%
Return on Equity (ttm)
-91.34%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.95M
Diluted EPS (ttm)
-0.6900
Balance Sheet and Cash Flow
Total Cash (mrq)
14.27M
Total Debt/Equity (mrq)
2.39%
Levered Free Cash Flow (ttm)
-10.86M